Table I.
Patient baseline characteristics.
| Patient no. | Gender | Age (years) | Ann Arbor stage | IPI | No. of previous chemotherapy regimens | Remission status before autologous SCT | Remission status after autologous SCT | Status post- rituximab maintenance (months) |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 36 | III | 2 | 6 | CR1 | CR | CCR 57+ |
| 2 | M | 30 | III | 2 | 6 | CR1 | CR | CCR 55+ |
| 3 | F | 28 | IV | 3 | 7 | CRu1 | CR | CCR 55+ |
| 4 | M | 36 | IV | 3 | 6 | CR1 | CR | CCR 53+ |
| 5 | M | 18 | III | 2 | 6 | CR1 | CR | CCR 53+ |
| 6 | M | 63 | III | 3 | 6 | CRu1 | CR | CCR45+ |
| 7 | F | 45 | IV | 3 | 9 | Relapse 1 sensitive (CRu) | CR | CCR41+ |
| 8 | M | 55 | III | 2 | 6 | CRu1 | CRu | Relapse, CR |
| 9 | M | 47 | IV | 3 | 9 | Relapse sensitive (CRu)1 | CR | Relapse, CR |
| 10 | F | 35 | IV | 2 | 6 | CR1 | CR | CCR 35+ |
| 11 | F | 60 | III | 2 | 8 | Relapse 1 sensitive (CRu) | CR | CCR 34+ |
| 12 | F | 57 | IV | 4 | 7 | CR1 | CR | CCR 33+ |
IPI, International Prognostic Index; SCT, stem-cell transplantation; CR, complete remission; CRu, unconfirmed complete remission; CCR, continuous complete remission.